ATE318935T1 - Bewertungssystem für die vorhersage von krebsrezidiven - Google Patents

Bewertungssystem für die vorhersage von krebsrezidiven

Info

Publication number
ATE318935T1
ATE318935T1 AT01951968T AT01951968T ATE318935T1 AT E318935 T1 ATE318935 T1 AT E318935T1 AT 01951968 T AT01951968 T AT 01951968T AT 01951968 T AT01951968 T AT 01951968T AT E318935 T1 ATE318935 T1 AT E318935T1
Authority
AT
Austria
Prior art keywords
cancer
recurrence
prediction
proteins
chip
Prior art date
Application number
AT01951968T
Other languages
English (en)
Inventor
Masaaki Oka
Yoshiko Hamamoto
Hisafumi Okabe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE318935T1 publication Critical patent/ATE318935T1/de

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT01951968T 2001-07-23 2001-07-23 Bewertungssystem für die vorhersage von krebsrezidiven ATE318935T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/006330 WO2003010337A1 (en) 2001-07-23 2001-07-23 Scoring system for the prediction of cancer recurrence

Publications (1)

Publication Number Publication Date
ATE318935T1 true ATE318935T1 (de) 2006-03-15

Family

ID=11737575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01951968T ATE318935T1 (de) 2001-07-23 2001-07-23 Bewertungssystem für die vorhersage von krebsrezidiven

Country Status (9)

Country Link
US (2) US7747389B2 (de)
EP (1) EP1409716B1 (de)
JP (1) JP4353796B2 (de)
CN (1) CN100398663C (de)
AT (1) ATE318935T1 (de)
CA (1) CA2455649C (de)
DE (1) DE60117555T2 (de)
ES (1) ES2254450T3 (de)
WO (1) WO2003010337A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254450T3 (es) 2001-07-23 2006-06-16 F. Hoffmann-La Roche Ag Sistema de evaluacion para predecir la recidiva del cancer.
GB2398379A (en) * 2003-02-11 2004-08-18 Qinetiq Ltd Automated digital image analysis
JP4698228B2 (ja) 2003-04-08 2011-06-08 エフ．ホフマン−ラ ロシュ アーゲー 腫瘍の分化段階を規定する方法
WO2004092365A1 (ja) * 2003-04-13 2004-10-28 Kyushu Tlo Company Limited 肝障害関連遺伝子群の抽出選択法およびそれを用いた肝障害もしくは肝機能評価・診断方法
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
EP1661991A4 (de) * 2003-08-24 2007-10-10 Univ Nihon Mit hepatozellulärem karzinom assoziiertes gen
FR2861744A1 (fr) * 2003-11-05 2005-05-06 Biomerieux Sa Procede pour le pronostic du cancer du sein
US8135595B2 (en) 2004-05-14 2012-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Computer systems and methods for providing health care
FR2881143B1 (fr) * 2005-01-27 2010-12-17 Librophyt Systeme de production de terpenoides dans les plantes
US20070072175A1 (en) * 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
KR101133243B1 (ko) * 2009-10-29 2012-04-06 국립암센터 암의 진단 및 치료를 위한 ｅＩＦ３ｍ의 용도
CN104200060A (zh) * 2014-07-30 2014-12-10 福建医科大学附属第一医院 预测巨大肝癌患者术后近期复发转移概率的模型及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5862304A (en) 1990-05-21 1999-01-19 Board Of Regents, The University Of Texas System Method for predicting the future occurrence of clinically occult or non-existent medical conditions
US6025128A (en) 1994-09-29 2000-02-15 The University Of Tulsa Prediction of prostate cancer progression by analysis of selected predictive parameters
US5800347A (en) 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
EP0957749A2 (de) 1995-09-12 1999-11-24 The General Hospital Corporation Verfahren zur früherkennung des eierstockrebs
AU7830598A (en) 1997-06-10 1998-12-30 Michael A. Levine Methods for thyroid cell detection
US6128608A (en) * 1998-05-01 2000-10-03 Barnhill Technologies, Llc Enhancing knowledge discovery using multiple support vector machines
DE19840671A1 (de) * 1998-08-26 2000-03-02 Stiftung Tumorbank Basel Verfahren zur Diagnose von Rezidiven bei nodal-negativem Brustkrebs
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
JP2003503770A (ja) 1999-06-29 2003-01-28 インターセット リミテッド ヒト癌仮想シミュレーション装置
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
EP1283904A2 (de) 1999-11-03 2003-02-19 Oncotech, Inc. Diagnose von krebs mit zellsortierung und genexpressionsprofilen
US6703202B2 (en) 1999-11-30 2004-03-09 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
WO2002077895A2 (en) * 2001-03-26 2002-10-03 Epigenomics Ag Method for epigenetic feature selection
US6728642B2 (en) 2001-03-29 2004-04-27 E. I. Du Pont De Nemours And Company Method of non-linear analysis of biological sequence data
WO2002103030A2 (en) * 2001-06-14 2002-12-27 Rigel Pharmaceuticals, Inc. Multidimensional biodata integration and relationship inference
ES2254450T3 (es) 2001-07-23 2006-06-16 F. Hoffmann-La Roche Ag Sistema de evaluacion para predecir la recidiva del cancer.
JP4698228B2 (ja) 2003-04-08 2011-06-08 エフ．ホフマン−ラ ロシュ アーゲー 腫瘍の分化段階を規定する方法

Also Published As

Publication number Publication date
CN1549864A (zh) 2004-11-24
JP2004536610A (ja) 2004-12-09
CN100398663C (zh) 2008-07-02
JP4353796B2 (ja) 2009-10-28
US8655597B2 (en) 2014-02-18
DE60117555T2 (de) 2007-01-11
ES2254450T3 (es) 2006-06-16
EP1409716A1 (de) 2004-04-21
WO2003010337A1 (en) 2003-02-06
CA2455649C (en) 2009-11-10
EP1409716B1 (de) 2006-03-01
US20120065892A1 (en) 2012-03-15
DE60117555D1 (de) 2006-04-27
US20040234988A1 (en) 2004-11-25
CA2455649A1 (en) 2003-02-06
US7747389B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
Tu et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues
ATE318935T1 (de) Bewertungssystem für die vorhersage von krebsrezidiven
Mansson et al. Pearson Correlation Analysis of Microarray Data Allows for the Identification of Genetic Targets for Early B-cell Factor*[boxs]
BR0212211A (pt) Diagnóstico de carcinomas
Amatschek et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
WO2007041342A3 (en) Labeled nucleotide analogs and uses therefor
DE69938623D1 (de) Microarrays und ihre verwendungen
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2003052099A3 (en) Methods of parallel gene cloning and analysis
WO2002014550A3 (en) Transcription factor target gene discovery
AR044099A1 (es) Pronostico de cancer de mama
Higuchi et al. Differentially expressed genes associated with cis‐diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray
McDonald et al. Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes
Saito et al. Detection of genes expressed in primary colon cancers by in situ hybridisation: overexpression of RACK 1
CA2521876A1 (en) Method of defining the differentiation grade of tumor
Wang Finding primary targets of transcriptional regulators
RU2005128277A (ru) Антитело против опухолеспецифичных антигенов в качестве мишени
TW200712493A (en) Tumor marker for ovarian cancer diagnosis
DE69734199D1 (de) Menschliches netrin-1
SE9900615L (sv) Metod och kit för tidig förutsägelse av cancer
Schmid et al. Expression of MUC I Splice Variants Correlates with Invasive Growth of Breast Cancer Cell Lines
KR100974228B1 (ko) 최기형성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 최기형성 및 부작용 유발 약물 검색 방법
WO2005060626A3 (en) Metal ion mediated fluorescence superquenching assays, kits and reagents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties